Available online on 15.12.2025 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research



Open Access

Review Article

Good Manufacturing Practices and Documentation in Pharmaceutical Production: A Comprehensive Review

Pallavi Gorukanti[1], Satheesh Jogala[2], Narender Boggula[1], Sucharitha Makula[1*]

[1]Omega College of Pharmacy, Edulabad, Ghatkesar, Hyderabad, Telangana, India.

[2]Research Scientist, Hetero Healthcare Limited, Hyderabad, Telangana, India.

A B S T R A C T

Good Manufacturing Practices (GMP) and thorough documentation systems are the backbone of pharmaceutical manufacturing. They ensure that every medicine produced meets strict quality, safety, and efficacy standards that patients depend on. This paper explores how GMP compliance and documentation work together in pharmaceutical production, looking at their regulatory basis, real-world applications, and strategic value in today's manufacturing landscape.The pharmaceutical industry faces unique pressures. When quality fails, patients suffer. That is why GMP exists-not as bureaucratic red tape, but as a systematic framework ensuring that medicines are made right, every single time. GMP covers everything from how facilities are designed and maintained to how employees are trained and how processes are validated.This review examines GMP fundamentals and documentation requirements across global regulatory systems. We analyze frameworks like the FDA's 21 CFR Part 211, the European Union's EudraLex Volume 4, ICH guidelines (Q7 and Q10), and WHO standards. We also dive into practical implementation-how to create effective Standard Operating Procedures (SOPs), maintain batch records, manage deviations, and handle electronic documentation systems. The paper also addresses evolving data integrity standards like ALCOA+ and how quality management principles like risk assessment and continuous improvement integrate into pharmaceutical operations.

Key words: Good Manufacturing Practices, ICH guidelines, validation, batch production record, quality risk management.

A R T I C L E I N F O: Received10 Sept. 2025; Review Complete 24 Oct. 2025; Accepted 18 Nov. 2025; Available online 15 Dec. 2025

Cite this article as:
Gorukanti P, Jogala S, Boggula N, Makula S, Good Manufacturing Practices and Documentation in Pharmaceutical Production: A Comprehensive Review, Asian Journal of Pharmaceutical Research and Development. 2025; 13(6):87-95,
DOI: http://dx.doi.org/10.22270/ajprd.v13i6.1676

*Address for Correspondence:
Sucharitha Makula, Assistant Professor, Omega College Of Pharmacy,Edulabad, Ghatkesar, Hyderabad, Telangana, India

INTRODUCTION

The pharmaceutical industry operates under intense regulatory scrutiny, and for good reason-the quality and safety of medicines directly affect patient health and public confidence. At the core of this industry sits Good Manufacturing Practice (GMP), a comprehensive regulatory framework designed to ensure pharmaceutical products are consistently produced and controlled according to quality standards appropriate for their use.GMP is not just one thing-it is a whole system of guidelines addressing every facet of pharmaceutical manufacturing. From facility design and equipment maintenance to personnel qualifications and process validation, GMP covers it all. The relationship between GMP and documentation is symbiotic. GMP creates the framework for quality assurance, while documentation provides tangible evidence that this framework is being followed day in and day out.Without well-structured, accurate documentation, manufacturers cannot adequately prove their operations meet GMP requirements. This is not about checking boxes-it is about creating a reliable evidence trail showing that quality is built into every step of production (1,2).

Scope and objectives

This paper takes a comprehensive look at GMP and documentation requirements in pharmaceutical production within the context of global regulatory expectations. We will examine how different regulatory bodies approach these requirements and explore practical strategies for implementing effective documentation systems. We will also look at emerging challenges like maintaining data integrity in

electronic systems and achieving continuous improvement while staying compliant (1,3).

Regulatory Framework and Foundational Principles of GMP

Evolution and global recognition of GMP:

Good Manufacturing Practice standards have an interesting history. They started in the late 1960s when the World Health Assembly recommended GMP provisions as part of the WHO Certification Scheme for pharmaceutical products in international commerce. The WHO's first draft text on GMP came out in 1968, and by 1969, the World Health Assembly recognized GMP as a crucial part of quality assurance.Over the past fifty-plus years, GMP has evolved dramatically. Today, more than 100 countries have incorporated WHO GMP provisions into their national medicine laws, while many others have adopted similar approaches when defining their own national GMP requirements. This widespread adoption shows how essential these standards have become to global pharmaceutical manufacturing.

The core principle underlying GMP represents a significant shift in thinking: quality must be built into the manufacturing process itself, not just tested into the final product. This paradigm shift reflects the pharmaceutical industry's realization that comprehensive quality assurance throughout production works far better than trying to inspect quality into products after they are made.GMP operates on ten core principles designed to minimize the risks that come with pharmaceutical production. These principles particularly focus on preventing two critical types of risk: cross-contamination and mix-ups, along with false labeling and inadequate product specifications (2-5).

Key GMP Principles and Quality Assurance Elements

The foundation of GMP rests on several interconnected principles that work together to ensure product safety and efficacy.

Manufacturing processes must be properly defined and controlled: This means having clearly documented procedures and instructions written in plain language that people can understand. Every critical process needs to be validated to ensure it consistently delivers results that meet predetermined specifications. The results of this process validation must be documented and kept available for regulatory inspection.

Quality assurance is paramount in GMP frameworks: Quality units need enough authority and resources to make sure all operations comply with established procedures and regulatory requirements. Quality personnel must review every aspect of manufacturing-from when raw materials arrive through when finished products ship out. They must stay independent from production pressures and have the authority to reject any batch or material that does not meet specifications.

Personnel are a critical quality factor: Everyone involved in pharmaceutical manufacturing-production staff, quality control, quality assurance-must receive appropriate training specific to their responsibilities. This training must address both technical skills and regulatory requirements, making sure employees understand not just how to do their jobs but why following established procedures matters so much for patient safety.

Environmental controls and facility maintenance are fundamental GMP requirements: Manufacturing facilities must be designed, built, and maintained to support proper operations, prevent cross-contamination, and maintain appropriate environmental conditions. Equipment must be properly designed, installed, calibrated, and maintained to ensure manufacturing processes stay within established parameters and produce consistent results (4,6-8).

Documentation Systems in GMP Compliance

Purpose and scope of pharmaceutical documentation: Documentation in pharmaceutical manufacturing serves several critical functions within the quality management system. At its most basic level, documentation provides the evidence trail proving all manufacturing operations comply with approved procedures and regulatory requirements. This evidence trail-called an audit trail-lets investigators reconstruct the complete history of any batch, from when raw materials arrive through final product distribution, including all processing steps, environmental conditions, and quality control testing performed along the way.

The scope of pharmaceutical documentation extends across the entire product lifecycle. During product development, documentation captures decisions about formulation composition, manufacturing process design, analytical methods, stability characteristics, and regulatory strategy. During commercial manufacturing, documentation includes batch records, quality control results, in-process controls, and equipment maintenance records. After product distribution, documentation records customer complaints, product investigations, and any market recalls or corrective actions taken (9,10).

Types of documentation in GMP facilities

Pharmaceutical facilities maintain multiple categories of documentation, each serving distinct but complementary functions within the quality management system. The documentation hierarchy typically includes:

- **Quality Manuals** outline the organization's overall quality policies and commitments. These high-level documents articulate what the company stands for in terms of quality.
- **Manufacturing Formula Records** specify all starting materials, processing parameters, and packaging materials for each product. These are the recipes, essentially.
- **Standard Operating Procedures** provide detailed instructions for routine operations. These are the step-by-step guides that ensure consistency.
- **Batch Production Records** document the actual execution of manufacturing operations for each specific batch. These show what actually happened during manufacturing.
- **Supporting Records** include quality control results, equipment maintenance logs, and employee training documentation. These provide additional evidence of compliance.

- **Quality Manuals and Quality System Documentation** serve as the foundation for all manufacturing operations. These documents express the organization's commitment to quality, define the structure and responsibilities of the quality management system, and outline the high-level procedures that govern manufacturing operations. Quality manuals typically reference subordinate documents such as SOPs and departmental procedures that provide detailed implementation guidance.
- **Master Formula Records (MFR) and Master Production and Control Records (MPCR)** specify the complete recipe and processing instructions for each pharmaceutical product. These documents identify all starting materials with their specifications and quantities, describe all processing steps in sequence, identify equipment used in production, specify critical process parameters with their acceptable ranges, outline in-process controls and their acceptance criteria, describe packaging operations and labeling requirements, and identify any additional operations such as environmental monitoring or stability sampling.The master formula record stays constant across all production batches of a given product, providing the baseline against which actual batch execution is compared. This consistency is crucial-it is what enables manufacturers to ensure every batch is made the same way.
- **Standard Operating Procedures (SOPs)** are written instructions describing how to perform specific operations consistently and efficiently. SOPs exist for virtually every aspect of pharmaceutical manufacturing-from general topics like cleaning procedures, equipment operation, and environmental monitoring to product-specific procedures for manufacturing particular drugs.Well-written SOPs provide step-by-step instructions with enough detail that trained personnel can perform operations consistently, reducing variability and ensuring all batches are manufactured under equivalent conditions. SOPs should specify the materials and equipment required, describe detailed procedural steps in logical sequence, identify safety and compliance considerations, specify acceptance criteria for process parameters, and include revision history documenting all changes to the procedure.
- **Batch Production Records (BPR)** represent the executed version of the Master Production Record for a specific batch. Batch production records capture all data generated during manufacturing, including: quantities of materials used, times of processing steps, equipment used, personnel involved, results of in-process controls, any deviations or variations from the approved procedure, investigations of deviations, yield calculations, and approvals by quality personnel authorizing release.These records provide contemporaneous documentation demonstrating the batch was manufactured exactly as approved and meets all quality specifications. They are legal documents that stand up in court if necessary.
- **Quality Control and Analytical Records** document all testing performed on raw materials, in-process samples, and finished products. These records include analytical methods used, reference standards employed, calibration status of testing equipment, actual results obtained, acceptance criteria, and conclusions regarding conformance to specifications. Supporting documentation includes chromatograms, spectra, and calculations that provide the raw data underlying reported results (5,11-14).

Regulatory Frameworks Governing Documentation and GMP

FDA 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals: In the United States, pharmaceutical manufacturing is governed by 21 CFR Part 211, the FDA's regulation establishing current Good Manufacturing Practice (cGMP) requirements for the preparation of drug products. This comprehensive regulation has 11 major sections covering buildings and facilities, equipment, controls on components and drug product containers, production and process controls, defect investigation and corrective action, records and reports, returned and salvaged drug products, specific requirements for finished pharmaceuticals, and administrative provisions.

Regarding documentation specifically, Section 211.180 establishes general requirements for records, specifying that records must be readily available for inspection and retained for periods appropriate to support regulatory oversight. The regulation requires that all data relative to manufacturing and quality control be recorded during actual performance of each operation by the person responsible for that operation. This creates a contemporaneous record that cannot be altered retroactively-an important protection against data manipulation.

Section 211.186 requires manufacturers to maintain master records for each dosage form and strength, ensuring uniformity from batch to batch. Section 211.188 specifies detailed requirements for batch production and control records, which must contain complete information relating to production and control of each batch (5,15,16).

European Medicines Agency EudraLex Volume 4: EU GMP Guidelines

The European Union's approach to GMP is codified in EudraLex Volume 4, which provides guidance for interpreting the principles and guidelines of good manufacturing practice for medicinal products. The EudraLex guideline has been adopted across EU member states and significantly influences GMP practices in other countries. EudraLex Volume 4 is organized into nine chapters addressing pharmaceutical quality systems, personnel, premises and equipment, documentation, production, quality control, outsourced activities, complaints and product recalls, and self-inspection.

Chapter 4 of EudraLex specifically addresses documentation and establishes that documentation is an essential part of the quality assurance system. Its aim is to define the specifications for all materials and manufacturing methods, ensure all personnel have access to necessary information to make quality decisions, and provide an audit trail permitting investigation of batch history.

EudraLex establishes that documentation must be retained for specified periods-typically at least one year after batch expiry for batch records, five years for API records, and longer for stability supporting data. Documents must be approved

before use, indicating that content is correct and consistent with other procedures, and must include version control mechanisms ensuring only the current approved version is in use.

ICH Guidelines: Q7, Q9, and Q10

The International Council for Harmonisation (ICH) has developed guidelines that have become recognized globally and are incorporated into regulatory requirements in numerous countries.

ICH Q7 provides guidance on Good Manufacturing Practice for Active Pharmaceutical Ingredients, emphasizing that a quality management system should be established to ensure continual improvement and strict compliance with regulatory requirements. The guideline promotes maintaining detailed and accurate records and documentation to ensure traceability and accountability, and establishes standards covering process validation, contamination control, and monitoring of critical process parameters.

ICH Q9, addressing Quality Risk Management, provides a systematic approach to evaluating risks associated with pharmaceutical operations. The guideline establishes that risk management is a science-based approach that identifies potential hazards, evaluates their likelihood and consequences, and determines control measures to mitigate identified risks. Risk management principles apply to documentation decisions, including determining which operations require comprehensive documentation and which deviations warrant investigation based on their potential impact on product quality.

ICH Q10, the Pharmaceutical Quality System guideline, provides a comprehensive model for a quality management system applicable across the entire product lifecycle from development through commercial manufacturing and product discontinuation. ICH Q10 establishes that the quality system should encompass product design, manufacturing process development and validation, commercial manufacturing operations including production and quality control, and ongoing product assessment and continuous improvement.

The guideline emphasizes that documentation should support all aspects of the pharmaceutical quality system, with particular emphasis on demonstrating that processes remain in a state of control through continuous monitoring and data-driven decision-making. This is the modern approach-using data to drive decisions rather than just following procedures blindly (7,17-19).

Standard Operating Procedures: Critical Documentation for Consistency and Compliance

Development and Structure of Effective SOPs: Standard Operating Procedures represent the fundamental mechanism through which pharmaceutical manufacturers ensure operations are performed consistently, with the same results, regardless of which individual performs the operation. In the pharmaceutical industry, SOPs are not optional convenience tools-they're regulatory requirements established by the FDA, EMA, WHO, and other regulatory bodies.

Well-developed SOPs provide necessary assurance that all personnel, whether newly hired or highly experienced, will perform operations in a manner that ensures product quality and meets regulatory requirements. This is especially important in an industry where people's health is on the line.

Effective SOPs follow a consistent structure that makes them easy to understand and implement. The structure typically begins with a title and SOP number that clearly identifies the operation being described, followed by a purpose section that explains why the procedure exists and what it accomplishes. A scope section delineates which operations, departments, or products the SOP applies to and identifies circumstances under which the procedure should be followed. A definitions section clarifies technical terms or regulatory concepts that may not be universally understood by all personnel who must use the SOP.

The primary procedural section provides step-by-step instructions written in clear, unambiguous language with a level of detail appropriate for personnel who may have limited familiarity with the operation. Each step should be numbered sequentially and should describe a single, discrete action, making it possible for an individual to verify that each step has been completed (6,20,21).

Role of SOPs in Regulatory Compliance and Risk Mitigation

Standard Operating Procedures fulfil multiple critical functions within pharmaceutical quality systems beyond their obvious role in ensuring consistency of operations.

SOPs demonstrate regulatory compliance by providing documented evidence that all critical operations are performed in a controlled manner according to approved procedures. During regulatory inspections, regulators specifically review SOPs to verify that operations critical to product quality are adequately specified and that personnel have access to clear guidance. Inadequate or outdated SOPs represent a common observation in FDA warning letters and regulatory inspections.

SOPs serve as essential risk mitigation tools by standardizing processes in a manner that reduces the likelihood of errors, contamination, and other deviations that could compromise product quality or patient safety. By specifying exact procedures, material quantities, equipment settings, and acceptance criteria, SOPs dramatically reduce the variation that can occur when different individuals perform the same operation according to their own understanding or interpretation. This reduction in variation contributes directly to product consistency and reduces the likelihood that batches will fail to meet specifications or deviate from approved procedures.

SOPs function as invaluable training tools that facilitate knowledge transfer and preserve institutional knowledge. New employees require comprehensive training on procedures critical to their assigned responsibilities, and SOPs provide a standardized reference that can be supplemented with on-the-job training and supervised practice. The existence of well-documented SOPs ensures that critical processes are not dependent on the expertise of a single individual, reducing business risk should that individual leave the organization. Furthermore, SOPs preserve procedural knowledge even as employee turnover occurs, maintaining continuity in manufacturing operations.

SOPs support continuous improvement by documenting the current understanding of how operations should be performed based on accumulated scientific and operational knowledge. Regular review and updating of SOPs provide opportunities to incorporate lessons learned from manufacturing experience, incorporate new scientific understanding, and implement process improvements that increase efficiency or quality. When SOPs are reviewed systematically and updated when improvements are identified, the organization demonstrates a commitment to science-based continuous improvement that regulatory agencies value highly (22-24).

Master Production Records and Batch Execution Documentation

Master Production and Control Records (MPCR) serve as the approved blueprint for manufacturing each pharmaceutical product. They specify in meticulous detail exactly how the product should be manufactured, what materials should be used in what quantities, what processing conditions should be maintained, and what in-process controls should be performed with what acceptance criteria.The master record stays essentially constant across all production batches of a given product, providing the baseline against which actual batch execution is compared. 21 CFR Part 211.186 specifically requires that master records be maintained for each dosage form and strength to ensure uniformity from batch to batch. This is crucial-without a consistent master record;there is no way to ensure batches are comparable.

When a batch is manufactured, a Batch Production Record (BPR) is created by copying the Master Production Record and then completing it with actual data as manufacturing operations are performed. The completed BPR captures: actual quantities of materials used, actual times of processing steps, actual equipment used, actual results of in-process tests with the names of the individuals who performed the tests, signatures and dates authorizing the release of materials for subsequent processing steps, any deviations from the approved procedure with documentation of the deviation, investigation, and corrective actions, calculations of final yield, and ultimately, the approval signature of quality personnel authorizing release of the batch for distribution (9,25,26).

Cleaning and Environmental Control Documentation

Pharmaceutical manufacturing equipment is often used to manufacture multiple different products on a production line, with equipment being cleaned between products to prevent cross-contamination. Cleaning and environmental control documentation represents a critical category of manufacturing records that provides evidence that equipment has been adequately cleaned and that manufacturing environments maintain appropriate controls for the products being manufactured.

Cleaning validation represents a key regulatory expectation, requiring documented evidence that established cleaning procedures consistently remove residues to acceptable levels. A cleaning validation protocol typically begins with a risk assessment identifying the "worst-case" combination of product and equipment that would be most challenging to clean, then specifies sampling locations, analytical methods used to detect residues, and acceptance criteria for cleanliness.Validation typically involves performing the cleaning procedure multiple times, typically a minimum of three runs, and demonstrating that residue levels remain below established acceptance criteria. Once a cleaning procedure is validated, routine monitoring must continue, with regular sampling and testing to confirm that cleaning remains effective.

Environmental monitoring records document that manufacturing areas maintain appropriate environmental conditions. For example, cleanroom classifications require maintenance of specific particle counts and microbiological contamination levels, which must be monitored regularly and documented.

Equipment use logbooks record which pieces of equipment were used in production on specific dates, the products manufactured using each piece of equipment, and the times of use. This documentation proves that equipment used to manufacture particular products is identified and that the sequence of equipment usage supports appropriate cleaning between products (6,27,28).

CAPA and Continuous Improvement

Following root cause analysis, Corrective Actions address the specific issue that occurred in the current batch, while Preventive Actions (collectively known as CAPA) address systemic issues that could lead to similar deviations in other batches or products.Corrective actions might include reworking a batch, destroying a batch if rework is not feasible, or verifying that similar deviations did not occur in other batches manufactured under similar conditions. Preventive actions typically involve implementing procedural changes, providing additional training, modifying equipment, or implementing additional controls to reduce the likelihood of recurrence.

The FDA expects that CAPA implementations are followed by verification activities demonstrating that the corrective and preventive actions have been effective. This might involve monitoring additional batches to verify that the deviation does not recur, trending deviation data to identify whether the frequency or severity of similar deviations has decreased, or conducting sampling studies to verify that additional controls are functioning as intended.Documentation of CAPA verification closes the deviation investigation cycle, providing evidence that the organization has not only addressed the immediate issue but has implemented systematic improvements to prevent recurrence (10,29,30).

Data Integrity and Electronic Documentation Systems

ALCOA+ Principles for Data Integrity

Data integrity represents an increasingly important focus of regulatory attention in pharmaceutical manufacturing. The FDA, European Medicines Agency, and other regulatory agencies have emphasized that the reliability of pharmaceutical data depends on adherence to fundamental principles governing how data is recorded, stored, protected, and accessed.The ALCOA acronym, established by the FDA, defines five core principles that should be applied to all data in GMP facilities:

Attributable data includes clear identification of the individual or system responsible for generating each record, with timestamps and signatures indicating when the record was created and by whom. This enables investigators to contact the individual who created the data if clarification is needed and establishes accountability for data quality.

Legible data is readable throughout its entire lifecycle, whether in paper or electronic format. Paper records should be written in permanent ink using legible handwriting, with corrections made using single-line cross-outs signed and dated by the individual making the correction. Electronic records should be printed or displayed in readily readable format with adequate contrast and text size.

Contemporaneous data is recorded at the time the operation is performed, not reconstructed after the fact from memory or secondary records. This requirement reflects the understanding that contemporaneous documentation reflects actual conditions at the time the operation was performed, whereas retrospective documentation may be influenced by expectations or subsequent knowledge of results.

Original data exists in the form it was first recorded, or as a certified true copy that accurately reproduces the original data. This principle reflects concerns about data integrity in the electronic environment, where data can be easily modified or deleted without leaving traces. It requires that either original records be retained, or if copies are maintained, those copies must be certified as accurate reproductions of the original data.

Accurate data correctly represents what was performed or observed, avoiding transcription errors and maintaining consistency between the actual operation and the recorded data. Accuracy encompasses not only correctness of numerical values but also completeness of information and logical consistency between related data elements.The FDA later expanded ALCOA to **ALCOA+**, adding five additional principles:

- **Complete** data includes all data, including repeat tests or reanalysis, providing a complete picture of operations.
- **Consistent** data follows a systematic approach ensuring all analysis components are documented in a logical sequence.
- **Enduring** data is preserved in a manner that prevents degradation or loss.
- **Available** data can be accessed for review and audit throughout its lifecycle.
- **Traceable** data can be traced through all phases of its lifecycle, with any modifications documented and explained without obscuring the original information (11,30-33).

Process Validation and Quality Control

Stages of process validation: Process validation represents a critical GMP requirement, ensuring that pharmaceutical manufacturing processes are capable of reliably producing products that meet predetermined specifications. The FDA's lifecycle approach to process validation divides the process into three stages: Process Design, Process Qualification, and Continued Process Verification.

Stage 1: Process Design involves defining the commercial manufacturing process based on knowledge gained through product development and scale-up activities. During this stage, manufacturers identify critical process parameters (CPPs)-manufacturing factors that directly influence product quality-and critical quality attributes (CQAs)-product characteristics that are essential for product performance.

Stage 2: Process Qualification confirms that the manufacturing process and supporting systems perform as designed during commercial manufacturing. This stage includes:

- **Installation Qualification (IQ)** verifying that manufacturing equipment has been properly installed and is compliant with design specifications
- **Operational Qualification (OQ)** confirming that equipment performs according to specifications under actual operating conditions
- **Performance Qualification (PQ)** consisting of full-scale manufacturing runs using the commercial process, with intensive monitoring demonstrating that the process consistently produces product meeting specifications
- The data collected during process qualification provides the initial evidence that the process is capable of reliably producing quality products.

Stage 3: Continued Process Verification represents the ongoing assurance that the manufacturing process remains in a state of control during routine production. This stage involves systematic collection and analysis of manufacturing and quality data to ensure process parameters remain within established control limits and that product quality characteristics remain within specifications (12,34-36).

Quality Control Testing and Release Procedures

Quality control testing represents a critical function ensuring that pharmaceutical products meet all established specifications before release. Quality control departments typically perform three categories of testing: testing of incoming raw materials and components, in-process testing during manufacturing, and testing of finished product.

Raw Material Testing verifies that incoming materials meet specifications for identity, purity, potency, and physical properties before materials are used in manufacturing. Testing typically begins with a Certificate of Analysis (COA) from the material supplier, but GMP requirements specify that organizations should not rely solely on supplier COAs. Instead, periodic testing of incoming materials is performed to verify that supplier quality is consistent and that COAs can be relied upon.

In-Process Testing is performed during manufacturing to monitor that the process is functioning as expected and that intermediate products meet specifications before progression to subsequent manufacturing steps. In-process tests might include moisture content of granules, hardness of tablets, or active ingredient content of intermediate steps.

Finished Product Testing verifies that the final manufactured product meets all established specifications. Finished product testing is comprehensive, typically including:

- Identity testing confirming the presence of the active ingredient
- Potency testing determining the quantity of active ingredient relative to label claim
- Purity testing detecting unwanted contaminants
- Stability-indicating testing confirming that the product will maintain quality throughout its shelf life

Finished product release requires that quality control has completed all required testing, that results comply with established acceptance criteria, and that quality personnel have reviewed all manufacturing and testing data and determined that the batch is suitable for release. This final review is critical-it's the last line of defense before product reaches patients (13,37,38).

Change Control and Maintenance of Validated Systems

Change Control Process and Documentation: In pharmaceutical manufacturing, changes are not made casually or informally. Any change to equipment, facilities, processes, materials, or procedures must be managed through a formal change control process that ensures the change does not negatively impact product quality or validated system status. Change control management is mandatory under GMP requirements and represents a critical means through which pharmaceutical organizations maintain operational excellence and continuous improvement while ensuring that quality remains uncompromised.The change control process typically follows six sequential steps:

Step 1: Change Proposal or Request is initiated by personnel who have identified a need for a change. Examples of changes might include upgrading manufacturing equipment to improve efficiency, substituting a raw material supplier due to supply chain issues, modifying a cleaning procedure based on lessons learned from manufacturing experience, or changing packaging materials to address environmental concerns.

Step 2: Impact and Risk Assessment This assessment utilizes quality risk management principles, systematically identifying potential risks associated with the change and evaluating the likelihood and consequence of each identified risk.

Step 3: Approval is where authorized personnel review the change proposal and impact assessment and determine whether the change should be implemented. This approval reflects a formal decision that the benefits of the proposed change outweigh the identified risks and that appropriate mitigation strategies have been developed.

Step 4: Implementation of the change under controlled conditions, typically with enhanced monitoring and documentation to verify that the change functions as intended. For equipment changes, this might involve manufacturing multiple trial batches, comparing batch results to historical data, and verifying that the new equipment produces equivalent product quality.

Step 5: Verification and Effectiveness Check is where data collected during implementation is analyzed to confirm that the change has functioned as intended and that product quality has not been adversely affected. This verification must demonstrate that the change achieves its intended objective and that any adverse consequences identified during risk assessment have been adequately mitigated.

Step 6: Documentation and Closure of the change control, with all change documentation filed and made available for regulatory inspection. The complete change control file documents the rationale for the change, the risk assessment, approval by authorized personnel, implementation activities, effectiveness verification, and lessons learned that might inform future changes (4,38,39).

Quality Management Systems and Continuous Improvement

ISO 9001 Framework in Pharmaceutical Context: ISO 9001 represents an internationally recognized standard for quality management applicable across diverse industries, including pharmaceuticals. In the pharmaceutical industry, ISO 9001 complements GMP requirements by providing a framework for systematic quality management, risk-based decision-making, and continuous improvement. The current version, ISO 9001:2015, emphasizes risk-based thinking and process-oriented approaches to quality management.

The ISO 9001 quality management system is built upon seven fundamental principles that guide quality management decisions:

1. **Customer focus** - ensuring products consistently meet customer needs and regulatory requirements
2. **Leadership** - establishing commitment to quality and establishing organizational strategy
3. **Engagement of people** - ensuring employees at all levels understand quality requirements and are motivated to contribute to quality achievements.
4. **Process approach** - recognizing that organizational results are achieved through systematic management of interrelated processes.
5. **Improvement** - establishing mechanisms for continuous enhancement of quality through identification of problems and implementation of improvements.
6. **Evidence-based decision making** - utilizing data and information to support quality decisions rather than relying on intuition.
7. **Relationship management** - developing beneficial relationships with suppliers and other external stakeholders (12,40,41).

Risk Management and Quality Risk Assessment

ICH Q9, the Quality Risk Management guideline, establishes a systematic approach to evaluating risks associated with pharmaceutical operations and implementing appropriate controls. Quality risk management is not about risk elimination, which may be impossible or impractical; rather,

it's risk reduction to an acceptable level through implementation of appropriate control measures.The risk management process includes:

Risk Identification involves systematically identifying potential hazards and events that could adversely affect product quality. This might be accomplished through brainstorming sessions, review of historical manufacturing data, or systematic analysis of potential failure modes.

Risk Analysis involves evaluating each identified risk regarding its likelihood of occurrence and the consequence if it does occur. Organizations might employ tools such as Failure Mode and Effects Analysis (FMEA) to systematically analyze potential failures, their consequences, and their detectability.

Risk Evaluation involves determining which risks are acceptable and which require mitigation. Organizations typically establish thresholds for acceptable risk based on regulatory requirements and organizational priorities, then focus mitigation efforts on risks exceeding those thresholds.

Risk Control involves implementing measures to mitigate identified risks to acceptable levels. Risk control measures might include process improvements, implementation of additional controls, or administrative procedures that reduce the likelihood of adverse events.

Throughout the pharmaceutical industry, quality risk management has become integral to GMP compliance, informing decisions about which processes require validation, which deviations warrant investigation, and how to allocate quality resources most effectively to protect product quality. This risk-based approach makes sense - it lets you focus resources where they are most needed rather than treating everything the same (2-4,42).

Implementation Challenges and Best Practices

Common Deficiencies Observed During Regulatory Inspections: FDA inspections consistently reveal common patterns of deficiencies in pharmaceutical manufacturing operations. Analysis of FDA warning letters demonstrates that documentation-related deficiencies represent one of the most frequently cited categories of violations.

Common documentation problems include:

- Incomplete or illegible batch records.
- Failure to document deviations.
- Missing signatures or approvals.
- Inconsistencies between recorded data and actual practices.
- Failure to maintain adequate records of equipment maintenance and cleaning validation.

Inadequate process validation represents another frequent deficiency category. FDA observations frequently cite incomplete or insufficient process validation studies, failure to validate critical manufacturing steps, or inadequate data demonstrating process capability.

Inadequate quality control practices include failure to test incoming materials, inadequate finished product testing, or inadequate investigation of out-of-specification results.

Personnel-related deficiencies are also frequently cited, including inadequate employee training on GMP and quality requirements, failure to provide initial and refresher training at appropriate intervals, and inadequate supervision to ensure that SOPs are followed as written.

Environmental control and cleaning deficiencies represent another common observation category, with inspectors frequently citing inadequate facility maintenance, insufficient environmental monitoring, or inadequate cleaning validation.These common deficiencies provide valuable guidance to pharmaceutical organizations regarding areas where regulatory focus is concentrated and where enhanced attention is warranted. If you want to stay out of trouble with regulators, these are the areas to focus on.

Strategies for Establishing Robust Quality Systems

Successful pharmaceutical organizations establish quality cultures where product quality is recognized as the paramount organizational priority and where all employees understand that their contributions support quality outcomes. This cultural foundation is established through leadership commitment to quality, evident in resource allocation decisions, training investments, and senior management's personal engagement with quality issues.

Technical excellence in quality systems is built through:

- Systematic documentation of all critical operations.
- Rigorous validation of all critical processes.
- Comprehensive employee training addressing both technical competencies and regulatory requirements.
- Disciplined adherence to established procedures (4-7,43).

CONCLUSION

Good Manufacturing Practice and comprehensive documentation systems represent interconnected pillars of quality assurance in the pharmaceutical industry, serving far more critical functions than simple compliance with regulatory checklists. GMP establishes the fundamental principles that pharmaceutical manufacturers must follow to ensure products are safe, effective, and meet established quality standards. Documentation provides the evidence trail demonstrating that these principles are being followed consistently across all manufacturing operations.The ultimate measure of success is not merely regulatory compliance, but the safe and effective delivery of high-quality medicines to patients throughout the world. That is what this is all about- protecting patients and ensuring they get the medicines they need when they need them.

Conflicts of interest

None declared.

REFERENCES

1. Food and Drug Administration. 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Code of Federal Regulations.

2. European Commission. EudraLex - Volume 4: Good Manufacturing Practice (GMP) Guidelines. Version 11, 2015.
3. International Council for Harmonisation. ICH Q7 Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. 2015.
4. International Council for Harmonisation. ICH Q9 Guideline: Quality Risk Management. 2005.
5. International Council for Harmonisation. ICH Q10 Guideline: Pharmaceutical Quality System. 2008.
6. World Health Organization. WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles. TRS 961, Annex 2.
7. Patel, K.T. Documentation and Records: Harmonized GMP Requirements. PDA Journal of Pharmaceutical Science and Technology, 2011.
8. Speach, M.E. The Critical Role of Standard Operating Procedures in the Pharmaceutical Industry. Pharmaceutical Research and Manufacturing, 2024.
9. Qualityze. Different Types of Batch Records in Pharmaceutical Industry. Quality Management Documentation Guide, 2025.
10. ValGenesis. Six Best Practices for ALCOA Data Integrity Success. GMP Compliance Blog, 2024.
11. The 1941 Sulfathiazole Disaster and the birth of Good Manufacturing Practices, John P Swann, Pharmacy in History, Vol 41, No 1, 1999; pp. 16-25.
12. Remington, The Science and Practice of Pharmacy, 21st ed, Volume 1, pp. 18-19.
13. ICH. Pharmaceutical Quality System Q10 Guideline. Step 5 Document, 2007.
14. FDA. GMP for Finished Pharmaceuticals: Records and Reports. Compliance Guidance, 2024.
15. Sandeep Bolla, Narender Boggula. Stability-indicating liquid chromatographic method for the simultaneous estimation of colchicine and rosuvastatin in combination. Essential Chem. 2025; 2(1):1-11.
16. Pharmaguideline. Change Control in Pharmaceuticals - GMP. Manufacturing Excellence, 2025.
17. Sanjay Kumar Jain, Rajesh Kumar Jain. Evolution of GMP in Pharmaceutical Industry. Research J. Pharm. and Tech. 2017; 10(2): 601-6.
18. Abdellah A, Noordin MI, Ismail WAW. Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients. Saudi Pharmaceutical Journal. 2015; 23(1):9-13.
19. Belhadi S, Trabelsi K, Limam Z. The impact of good manufacturing practices on pharmaceutical quality. International Journal of Quality & Reliability Management. 2019; 36(7):1226–42.
20. Pharmuni. Process Validation in Pharmaceutical Manufacturing. Regulatory Guide, 2025.
21. Code of federal regulations, title 21, Food and Drugs. Current Good Manufacturing practices in manufacturing, processing, packing or Holding of Drugs. Part 210-211.
22. A Brief History of the GMPs for Pharmaceuticals, Barbar K. Immel, Pharmaceutical Technology, July 2001;pp. 44-52.
23. Gouveia BG, Rijo P, Gonçalo TS, Reis CP. Good manufacturing practices for medicinal products for human use. Journal of Pharmacy & Bioallied Sciences. 2015;7(2):87.
24. Sharma A,Luthra G. A comprehensive review of risk management in the medical device industry. Journal of Pharmaceutical ResearchInternational. 2023;35(6):14–23.
25. Sharma A, Luthra G. Implementing a Risk-Based Approach to Quality Management System ISO-13485 Processes in Compliance with EUMDR 2017/745 for Medical Device Industry.Journalof PharmaceuticalResearch International. 2023;35:8–19.
26. Sharma A, Luthra G. Significance of ISO 10993 Standards in Ensuring Biocompatibility of MedicalDevices:A Review. Journal of Pharmaceutical Research International; 2023;35:23–34.
27. Rampal A, Yamini Kanti SP. Good Manufacturing Practice (GMP): History, structure and its significance. Int J Drug Reg Affairs. 2020;8(4):66-2.
28. Akash Sharma, Vriti Gamta, Gaurav Luthra. The Importance of Good Manufacturing Practices (GMP) in the Healthcare Industry. J. Pharm. Res. Int. 2023; 35(18): 75-90.
29. Dr. Bilal Ahmad Wani & Dr. Shaheen Ahmad mir Basics of Research Methodology and Medical Statistics for Ayuvedic Scholars, Ayurved Sasnskrit Hindi Pustak Bhandar Jaipur Part A Chp-12 Clinical research, 2021; 202-203.
30. Al Azawei A, Loughrey K, Surim K, Connolly ME and Naughton BD. The management of good manufacturing practice (GMP) inspections: a scoping review of the evidence. Front. Med. 2025; 12:1687864.
31. Male T, Vinod Kumar K, Chithra Shekar C, Srinkanth. A comprehensive review on comparison of gdocp in pharmaceutical manufacturing unit as per European and WHO guidelines. Int J Curr Pharm Res. 2021; 13:21–4.
32. Varin T, Waranon C, Narueporn S. Risk assessment of good manufacturing practice inspection of overseas pharmaceutical manufacturers based on desktop inspection as required in Thailand. Thai J Pharm Sci. 2023; 47:5–10.
33. Daniel T, Michael W, Juan-Antonio R, Simon B, Stephan B. Recent Regulatory Trends in Pharmaceutical Manufacturing and their impact on industry. Chimia. 2018; 72:146–50.
34. Tauqeer F, Myhr K, Gopinathan U. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study. Health Policy Plan. 2019; 34:440–9.
35. Reis C, Gouveia B, Rijo P, Gonçalo T. Good manufacturing practices for medicinal products for human use. J Pharm Bioallied Sci. 2015; 7:87–96.
36. Patel KT, Chotai NP. Documentation and records: harmonized GMP requirements. J Young Pharm. 2011; 3:138–50.
37. Chejor P, Dorji T, Dema N, Stafford A. Good manufacturing practice in low- andmiddle-income countries: Challenges and solutions for compliance. Public Health Chall. 2024;3:e158.
38. Chopra H, Attia MS, Badshah SF, Dhama K, Emran TB. Cough syrups: silent killer of Gambian children. Int J Surg. 2023;109(2):150-2.
39. Tauqeer F, Myhr K, Gopinathan U. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards inthe local pharmaceutical industry of Pakistan: a qualitative study. Health Policy Plan. 2019;34(6):440-9.
40. Lubowa N, Ekeocha Z, Byrn S, Clase K. Pharmaceutical industry in Uganda: a review of the common GMP non-conformances during regulatory inspections. In: BIRS Africa Technical Report Papers [Paper 10]. Purdue University; 2021.
41. Parry D. World good manufacturing practices. In: Bunn PG. Good Manufacturing Practices for Pharmaceuticals. 7thed. CRC Press; 2018; pp. 343-51.
42. Gostin LO, Wood AJ, Cuff PA. Regulating medicines in a globalized world with increased recognition and reliance among regulators: a National Academies report. JAMA. 2020;324(2):145-6.
43. Lund W. Good manufacturing practices. The pharmaceutical codex: principle and practice of pharmaceutics. London, 12th ed, The Pharmaceutical Press, 1994; pp. 362-97.